Merck KGaA Acquires SpringWorks Therapeutics

Merck KGaA, Darmstadt, Germany closed its acquisition of SpringWorks Therapeutics, Inc. in a deal with an enterprise value of $3.4 billion (about €3.0 billion). The acquisition adds SpringWorks’ rare tumor portfolio—including OGSIVEO (nirogacestat) and GOMEKLI (mirdametinib)—to Merck’s Healthcare business and is expected to accelerate growth in rare tumors and expand reach beyond the U.S.